Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Abdullatif Al Khedr, Dan Mikol et al.|The Lancet Neurology|2018Cited by 345
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimodMaryam Nakhaei‐Nejad, Fabrizio Giuliani, David Barilla et al.|Neurology Neuroimmunology & Neuroinflammation|2017Cited by 31
The Regulation of Reactive Changes Around Multiple Sclerosis Lesions by Phosphorylated Signal Transducer and Activator of TranscriptionJian‐Qiang Lu, V. Wee Yong, Christopher Power et al.|Journal of Neuropathology & Experimental Neurology|2013Cited by 16
Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profileChristopher C. Cheng, Christopher Power, Jennifer A. McCombe et al.|Neurological Sciences|2021Cited by 7
Differential disease phenotypes and progression in relapsing–remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinicsMohammad Alluqmani, Christopher Power, Weston Roda et al.|BMC Neurology|2021Cited by 6